About Exeltis
Exeltis is a company based in Madrid (Spain) founded in 2003. Exeltis has completed 1 acquisition, including Quinnova Pharmaceuticals. Exeltis offers products and services including Innovative Treatments and Nutritive Specialties. Exeltis operates in a competitive market with competitors including aTyr Pharma, ReCode Therapeutics, InterMune, GEn1E and Pulmatrix, among others.
- Headquarter Madrid, Spain
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Exeltis Pharmaceuticals Holding, S.L.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Exeltis
Exeltis offers a comprehensive portfolio of products and services, including Innovative Treatments and Nutritive Specialties.
Develops solutions for unmet medical needs
Provides nutritional products for health support
People of Exeltis
Unlock access to complete
Funding Insights of Exeltis
Investments & Acquisitions by Exeltis
Exeltis has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Quinnova Pharmaceuticals.
Investment portfolio details for Exeltis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
-
|
Locked | Locked | 2003 | Locked |
Complete acquisition details for Exeltis
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Exeltis
Detailed financials for Exeltis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Exeltis Comparisons
Peer comparison for Exeltis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Exeltis
Exeltis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as aTyr Pharma, ReCode Therapeutics, InterMune, GEn1E and Pulmatrix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Protein biologics are developed for treating rare diseases.
|
|
| Locked | Locked | Locked |
Precision medicines for lung-related diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies in pulmonology and orphan fibrotic diseases.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of inflammatory and rare diseases
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of respiratory diseases
|
|
| Locked | Locked | Locked |
Respiratory disease drugs for asthma and COPD are developed.
|
Detailed competitors of Exeltis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Exeltis
Complete news archive for Exeltis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Exeltis
Exeltis was founded in 2003.
Exeltis is headquartered in Madrid, Spain. It is registered at Madrid, Madrid, Spain.
Exeltis was founded in 2003 and is headquartered in Madrid, Spain. Therapeutics based on small molecules are developed by the company for conditions in areas such as respiratory health, endocrinology, dermatology, and womens health. The pipeline features products including Trifamox, indicated for upper and lower respiratory tract infections, and Eluzer, used in treating inoperable malignant pleural mesothelioma. Operations focus on pharmaceutical development within these sectors.
Exeltis's top competitors include aTyr Pharma, ReCode Therapeutics and Pulmatrix.
Exeltis offers Innovative Treatments and Nutritive Specialties.
Exeltis has made 1 acquisition, including Quinnova Pharmaceuticals.